Literature DB >> 9403706

Matrix vesicles in osteomalacic hypophosphatasia bone contain apatite-like mineral crystals.

H C Anderson1, H H Hsu, D C Morris, K N Fedde, M P Whyte.   

Abstract

Hypophosphatasia, a heritable disease characterized by deficient activity of the tissue nonspecific isoenzyme of alkaline phosphatase (TNSALP), results in rickets and osteomalacia. Although identification of TNSALP gene defects in hypophosphatasia establishes a role of ALP in skeletal mineralization, the precise function remains unclear. The initial site of mineralization (primary mineralization) normally occurs within the lumen of TNSALP-rich matrix vesicles (MVs) of growth cartilage, bone, and dentin. We investigated whether defective calcification in hypophosphatasia is due to a paucity and/or a functional failure of MVs secondary to TNSALP deficiency. Nondecalcified autopsy bone and growth plate cartilage from five patients with perinatal (lethal) hypophosphatasia were studied by nondecalcified light and electron microscopy to assess MV numbers, size, shape, and ultrastructure and whether hypophosphatasia MVs contain apatite-like mineral, as would be the case if these MVs retained their ability to concentrate calcium and phosphate internally despite a paucity of TNSALP in their investing membranes. We found that hypophosphatasia MVs are present in approximately normal numbers and distribution and that they are capable of initiating internal mineralization. There is retarded extravesicular crystal propagation. Thus, in hypophosphatasia the failure of bones to calcify appears to involve a block of the vectorial spread of mineral from initial nuclei within MVs, outwards, into the matrix. We conclude that hypophosphatasia MVs can concentrate calcium and phosphate internally despite a deficiency of TNSALP activity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9403706      PMCID: PMC1858375     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  28 in total

1.  Genetic, clinical, biochemical, and pathological features of hypophosphatasia; based on the study of a family.

Authors:  A M BARRETT; D V FAIRWEATHER; R A MCCANCE; A B MORRISON
Journal:  Q J Med       Date:  1956-10

2.  Mapping of the gene coding for the human liver/bone/kidney isozyme of alkaline phosphatase to chromosome 1.

Authors:  D M Swallow; S Povey; M Parkar; P W Andrews; H Harris; B Pym; P Goodfellow
Journal:  Ann Hum Genet       Date:  1986-07       Impact factor: 1.670

3.  Phosphatases of epiphyseal cartilage studied by electron microscopic cytochemical methods.

Authors:  T Matsuzawa; H C Anderson
Journal:  J Histochem Cytochem       Date:  1971-12       Impact factor: 2.479

4.  Hypophosphatasia: levels of bone alkaline phosphatase immunoreactivity in serum reflect disease severity.

Authors:  M P Whyte; D A Walkenhorst; K N Fedde; P S Henthorn; C S Hill
Journal:  J Clin Endocrinol Metab       Date:  1996-06       Impact factor: 5.958

5.  Histologic and ultrastructural studies on the mineralization process in hypophosphatasia.

Authors:  A Ornoy; G E Adomian; D L Rimoin
Journal:  Am J Med Genet       Date:  1985-12

6.  Aberrant properties of alkaline phosphatase in patient fibroblasts correlate with clinical expressivity in severe forms of hypophosphatasia.

Authors:  K N Fedde; M P Michell; P S Henthorn; M P Whyte
Journal:  J Clin Endocrinol Metab       Date:  1996-07       Impact factor: 5.958

7.  Calcification of rachitic cartilage to study matrix vesicle function.

Authors:  H C Anderson; S W Sajdera
Journal:  Fed Proc       Date:  1976-02

8.  A missense mutation in the human liver/bone/kidney alkaline phosphatase gene causing a lethal form of hypophosphatasia.

Authors:  M J Weiss; D E Cole; K Ray; M P Whyte; M A Lafferty; R A Mulivor; H Harris
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

9.  Infantile hypophosphatasia: normalization of circulating bone alkaline phosphatase activity followed by skeletal remineralization. Evidence for an intact structural gene for tissue nonspecific alkaline phosphatase.

Authors:  M P Whyte; H L Magill; M D Fallon; H G Herrod
Journal:  J Pediatr       Date:  1986-01       Impact factor: 4.406

10.  Vesicles associated with calcification in the matrix of epiphyseal cartilage.

Authors:  H C Anderson
Journal:  J Cell Biol       Date:  1969-04       Impact factor: 10.539

View more
  36 in total

1.  Impaired calcification around matrix vesicles of growth plate and bone in alkaline phosphatase-deficient mice.

Authors:  H Clarke Anderson; Joseph B Sipe; Lovisa Hessle; Rama Dhanyamraju; Elisa Atti; Nancy P Camacho; José Luis Millán; Rama Dhamyamraju
Journal:  Am J Pathol       Date:  2004-03       Impact factor: 4.307

2.  Skeletal mineralization defects in adult hypophosphatasia--a clinical and histological analysis.

Authors:  F Barvencik; F Timo Beil; M Gebauer; B Busse; T Koehne; S Seitz; J Zustin; P Pogoda; T Schinke; M Amling
Journal:  Osteoporos Int       Date:  2011-01-26       Impact factor: 4.507

Review 3.  Proteoliposomes in nanobiotechnology.

Authors:  P Ciancaglini; A M S Simão; M Bolean; J L Millán; C F Rigos; J S Yoneda; M C Colhone; R G Stabeli
Journal:  Biophys Rev       Date:  2012-01-18

4.  Alkaline phosphatase knock-out mice recapitulate the metabolic and skeletal defects of infantile hypophosphatasia.

Authors:  K N Fedde; L Blair; J Silverstein; S P Coburn; L M Ryan; R S Weinstein; K Waymire; S Narisawa; J L Millán; G R MacGregor; M P Whyte
Journal:  J Bone Miner Res       Date:  1999-12       Impact factor: 6.741

5.  Hypophosphatasia - pathophysiology and treatment.

Authors:  José Luis Millán; Horacio Plotkin
Journal:  Actual osteol       Date:  2012-09-01

6.  Sustained osteomalacia of long bones despite major improvement in other hypophosphatasia-related mineral deficits in tissue nonspecific alkaline phosphatase/nucleotide pyrophosphatase phosphodiesterase 1 double-deficient mice.

Authors:  H Clarke Anderson; Dympna Harmey; Nancy P Camacho; Rama Garimella; Joseph B Sipe; Sarah Tague; Xiaohong Bi; Kristen Johnson; Robert Terkeltaub; José Luis Millán
Journal:  Am J Pathol       Date:  2005-06       Impact factor: 4.307

7.  Asfotase alfa therapy for children with hypophosphatasia.

Authors:  Michael P Whyte; Katherine L Madson; Dawn Phillips; Amy L Reeves; William H McAlister; Amy Yakimoski; Karen E Mack; Kim Hamilton; Kori Kagan; Kenji P Fujita; David D Thompson; Scott Moseley; Tatjana Odrljin; Cheryl Rockman-Greenberg
Journal:  JCI Insight       Date:  2016-06-16

8.  Skeletal Mineralization Deficits and Impaired Biogenesis and Function of Chondrocyte-Derived Matrix Vesicles in Phospho1(-/-) and Phospho1/Pi t1 Double-Knockout Mice.

Authors:  Manisha C Yadav; Massimo Bottini; Esther Cory; Kunal Bhattacharya; Pia Kuss; Sonoko Narisawa; Robert L Sah; Laurent Beck; Bengt Fadeel; Colin Farquharson; José Luis Millán
Journal:  J Bone Miner Res       Date:  2016-05-17       Impact factor: 6.741

9.  Human PHOSPHO1 exhibits high specific phosphoethanolamine and phosphocholine phosphatase activities.

Authors:  Scott J Roberts; Alan J Stewart; Peter J Sadler; Colin Farquharson
Journal:  Biochem J       Date:  2004-08-15       Impact factor: 3.857

10.  Proteoliposomes harboring alkaline phosphatase and nucleotide pyrophosphatase as matrix vesicle biomimetics.

Authors:  Ana Maria S Simão; Manisha C Yadav; Sonoko Narisawa; Mayte Bolean; Joao Martins Pizauro; Marc F Hoylaerts; Pietro Ciancaglini; José Luis Millán
Journal:  J Biol Chem       Date:  2010-01-04       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.